VICTORIA, Australia, May 31, 2011 /PRNewswire/ — Genetic
Technologies Limited (ASX: GTG; NASDAQ:
GENE) has received and processed its first
BREVAGen™ clinical sample from a US patient.
This follows last month’s receipt of certification of its
Australian laboratory under the US Clinical Laboratories
Improvements Amendments (CLIA) (42 U.S.C. 263a).
The sample was received by Phenogen Sciences, the Company’s new
North American subsidiary, where the cheek swab sample was
bar-coded and entered into the Laboratory Information Management
System, before being priority shipped to Australia for processing.
Subsequently the results were made electronically accessible
to the Company’s North Carolina offices for immediate distribution
to the requesting physician. All systems functioned as
expected and no infrastructure hurdles remain to full market
The results enabled the patient’s physician to better understand
the personalized risk of non-familial breast cancer, allowing
better management and prevention of disease. The patient is
one of an estimated 1.3 million new patients annually in the US who
could benefit from such a test.
“64 percent of the target patient population will have their
breast cancer risk re-classified as a result of using the
BREVAGen™ test, providing a more personalized and
actionable assessment. Many women will have their peace of
mind improved by being re-classified to a lower risk group while
for others, they will be re-classified to a higher risk group,
enabling decisions regarding increased surveillance or even cancer
preventive therapy,” said Mr. Lewis Stuart, Phenogen Sciences
President and General Manager.
Concurrently, Phenogen Sciences has now hired its initial sales
team in preparation for the imminent launch of
BREVAGen™. Now at their inaugural s